CD95 ligand mediates T-cell receptor-induced apoptosis of a CD4+ CD8+ double positive thymic lymphoma

Oncogene

Volumn 25, Issue 58, 2006, Pages 7587-7596

  Schmitz, I ^a   Meyer, C ^a   Schulze Osthoff, K ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Caspase; CD95; Thymic lymphoma; Thymus

Indexed keywords

CASPASE; CD3 ANTIGEN; FAS ANTIGEN; MEMBRANE ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; ENZYME ACTIVATION; EPITHELIUM CELL; LYMPHOCYTE TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYMOCYTE; THYMOMA; THYMUS LYMPHOMA;

ANIMALS; ANTIGENS, CD3; ANTIGENS, CD8; APOPTOSIS; CASPASES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CLONAL DELETION; FAS LIGAND PROTEIN; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTEIN BIOSYNTHESIS; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; THYMUS NEOPLASMS;

EID: 33845541008     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209741     Document Type: Article

References (49)

1. Aisenberg AC. (1993). J Clin Oncol 11: 2291-2294.
2. Alam A, Braun MY, Hartgers F, Lesage S, Cohen L, Hugo P et al. (1997). J Exp Med 186: 1503-1512.
3. Berg LJ, Fazekas de St Groth B, Ivars F, Goodnow CC, Gilfillan S, Garchon HJ et al. (1988). Mol Cell Biol 8: 5459-5469.
4. Boehm T, Rabbitts TH. (1989). FASEB J 3: 2344-2359.
5. Caserta TM, Smith AN, Gultice AD, Reedy MA, Brown TL. (2003). Apoptosis 8: 345-352.
6. Castro JE, Listman JA, Jacobson BA, Wang Y, Lopez PA, Ju S et al. (1996). Immunity 5: 617-627.
7. Chahinian AP. (2003). In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF et al. (eds). Cancer Medicine, vol. 2. BC Decker Inc.: Hamilton, London, pp 1467-1477.
8. Chao DT, Korsmeyer SJ. (1998). Annu Rev Immunol 16: 395-419.
9. Clayton LK, Ghendler Y, Mizoguchi E, Patch RJ, Ocain TD, Orth K et al. (1997). EMBO J 16: 2282-2293.
10. Davis MM, Bjorkman PJ. (1988). Nature 334: 395-402.
11. Doerfler P, Forbush KA, Perlmutter RM. (2000). J Immunol 164: 4071-4079.
12. Fernandez E. (2000). Blood 95: 1356-1361.
13. Fischer U, Janicke RU, Schulze-Osthoff K. (2003). Cell Death Differ 10: 76-100.
14. Fischer U, Schulze-Osthoff K. (2005). Pharmacol Rev 57: 187-215.
15. Fuentes-Prior P, Salvesen GS. (2004). Biochem J 384: 201-232.
16. Geisler C. (2004). Crit Rev Immunol 24: 67-86.
17. Groves T, Katis P, Madden Z, Manickam K, Ramsden D, Wu G et al. (1995). J Immunol 154: 5011-5022.
18. Hanahan D, Weinberg RA. (2000). Cell 100: 57-70.
19. Hettmann T, DiDonato J, Karin M, Leiden JM. (1999). J Exp Med 189: 145-158.
20. Igney FH, Krammer PH. (2002). Nat Rev Cancer 2: 277-288.
21. Izquierdo M, Grandien A, Criado LM, Robles S, Leonardo E, Albar JP et al. (1999). EMBO J 18: 156-166.
22. Jiang X, Wang X. (2004). Annu Rev Biochem 73: 87-106.
23. Kaye J, Ellenberger DL. (1992). Cell 71: 423-435.
24. Kirchhoff S, Muller WW, Li-Weber M, Krammer PH. (2000). Eur J Immunol 30: 2765-2774.
25. Kovalik JP, Ansari B, Boothby M. (1996). J Immunol 157: 5290-5299.
26. Legembre P, Barnhart BC, Zheng L, Vijayan S, Straus SE, Puck J et al. (2004). EMBO Rep 5: 1084-1089.
27. Li H, Zhu H, Xu CJ, Yuan J. (1998). Cell 94: 491-501.
28. Los M, Wesselborg S, Schulze-Osthoff K. (1999). Immunity 10: 629-639.
29. Maeda T, Yamada Y, Moriuchi R, Sugahara K, Tsuruda K, Joh T et al. (1999). J Exp Med 189: 1063-1071.
30. Martin DA, Zheng L, Siegel RM, Huang B, Fisher GH, Wang J et al. (1999). Proc Natl Acad Sci USA 96: 4552-4557.
31. Matiba B, Mariani SM, Krammer PH. (1997). Semin Immunol 9: 59-68.
32. Moulian N, Berrih-Aknin S. (1998). Semin Immunol 10: 449-456.
33. Muschen M, Rajewsky K, Kronke M, Kuppers R. (2002). Trends Immunol 23: 75-80.
34. Namba T, Brunner NG, Grob D. (1978). Medicine (Baltimore) 57: 411-433.
35. Nishida T, Matsuki Y, Ono T, Oguma T, Tsujimoto K, Sato M et al. (2004). J Immunol 172: 6634-6641.
36. Peter ME, Krammer PH. (2003). Cell Death Differ 10: 26-35.
37. Rathmell JC, Thompson CB. (2002). Cell 109(Suppl): S97-S107.
38. Reichmann E. (2002). Semin Cancer Biol 12: 309-315.
39. Rosai J, Levine GD. (1976). Atlas of Tumor Pathology. Armed Forces Institute of Pathology: Washington, DC.
40. Sakahira H, Enari M, Nagata S. (1998). Nature 391: 96-99.
41. Sasada T, Reinherz EL. (2001). J Immunol 166: 2394-2403.
42. Schmitz I, Weyd H, Krueger A, Baumann S, Fas SC, Krammer PH et al. (2004). J Immunol 172: 2194-2200.
43. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME. (1998). Eur J Biochem 254: 439-459.
44. Sidman CL, Marshall JD, Von Boehmer H. (1992). Eur J Immunol 22: 499-504.
45. Sohn D, Totzke G, Essmann F, Schulze-Osthoff K, Levkau B, Janicke RU. (2006). Mol Cell Biol 26: 1967-1978.
46. Starr TK, Jameson SC, Hogquist KA. (2003). Annu Rev Immunol 21: 139-176.
47. Venanzi ES, Benoist C, Mathis D. (2004). Curr Opin Immunol 16: 197-202.
48. Wadsworth S, Yui K, Siegel RM, Tenenholz DE, Hirsch JA, Greene MI. (1990). Eur J Immunol 20: 723-730.
49. Yefenof E. (1999). Adv Immunol 73: 511-539.